Clinical trials: Estrogen Receptor-positive Breast Cancer
Breast Cancer
Vepdegestrant (ARV-471/PF-07850327) + Palbociclib vs Letrozole + Palbociclib in ER(+)/HER2(-) Advanced Breast Cancer
The purpose of this study is to understand the safety and effects of the study medicine vepdegestrant (ARV-471/PF-07850327) given together with palbociclib in advanced breast cancer.
- Trial name
- VERITAC-3 (NCT05909397)
- Testing
- Vepdegestrant (ARV-471/PF-07850327), Palbociclib, Letrozole
- Where
- 29 sites in United States, Australia and 8 more
- Volunteers
- 59 people
- Sponsor
- Pfizer
Anatomic Stage IV Breast Cancer AJCC v8, Estrogen Receptor Positive
Letrozole and Imatinib Mesylate in Treating Postmenopausal Participants With Estrogen or Progesterone Positive Metastatic Breast Cancer
This phase II trial studies the side effects and how well letrozole and imatinib mesylate work in treating postmenopausal participants with estrogen or progesterone positive breast cancer that has spread to other places in the…
- Conditions
- Anatomic Stage IV Breast Cancer AJCC v8, Estrogen Receptor Positive, KIT Positive, PDGFR Positive
- Trial name
- NCT00338728
- Testing
- Imatinib Mesylate, Letrozole
- Where
- United States
- Volunteers
- 59 people
- Sponsor
- M.D. Anderson Cancer Center
Adult Solid Neoplasm, Extensive Stage Lung Small Cell Carcinoma
RO4929097 and Whole-Brain Radiation Therapy or Stereotactic Radiosurgery in Treating Patients With Brain Metastases From Breast Cancer
This randomized phase I/II trial studies the side effects and the best dose of RO4929097 (gamma-secretase/Notch signalling pathway inhibitor RO4929097) when given together with whole-brain radiation therapy or stereotactic…
- Conditions
- Adult Solid Neoplasm, Extensive Stage Lung Small Cell Carcinoma, HER2/Neu Negative, HER2/Neu Positive
- Trial name
- NCT01217411
- Testing
- Cognitive Assessment, Gamma-Secretase Inhibitor RO4929097, Laboratory Biomarker Analysis
- Where
- 2 sites in United States
- Volunteers
- 5 people
- Sponsor
- National Cancer Institute (NCI)
Breast Neoplasms
Aromasin® As Adjuvant Treatment In Postmenopausal Women With Invasive, Estrogen Receptor Positive Early Breast Cancer
This non-interventional study will be conducted in several Eastern European countries to assess the safety, tolerability and efficacy of Aromasin® when it is administered in real-word setting in postmenopausal women with invasive…
- Trial name
- NCT01239745
- Testing
- Aromasin
- Where
- 11 sites in Croatia, Estonia and 1 more
- Volunteers
- 46 people
- Sponsor
- Pfizer
Primary Breast Cancer
[99mTc]Tc-DB8 Accumulation in Primary Tumor in Breast Cancer With Positive and Negative Estrogen Receptor Expression
The study should evaluate the [99mTc]Tc-DB8 accumulation in primary tumour of breast cancer patients with positive and negative estrogen receptor expression.
- Trial name
- NCT07275463
- Testing
- [99mTc]Tc-DB8
- Where
- Russia
- Volunteers
- 40 people
- Sponsor
- Tomsk National Research Medical Center of the Russian Academy of Sciences
Breast Cancer, Breast Cancer Female
Preoperative Stereotactic Ablative Body Radiotherapy (SABR) for Early-Stage Breast Cancer
This study involves a course of radiation to the tumor that is delivered BEFORE surgery. The type of radiation is called stereotactic ablative body radiation therapy (SABR).
- Conditions
- Breast Cancer, Breast Cancer Female, Breast Adenocarcinoma
- Trial name
- NCT03137693
- Testing
- Standard of Care Schedule Variation: SABR, Breast-conserving Surgery
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Breast Cancer
Study to Compare Zoladex™ 10.8 mg With Zoladex 3.6 mg in Pre-menopausal Women With Breast Cancer
The purpose of this study is to examine the efficacy and safety as well as the characteristics of the female hormone and study medications after administration in pre-menopausal women with estrogen receptor positive advanced…
- Trial name
- NCT01073865
- Testing
- ZD9393 (Zoladex) 10.8 mg, ZD9393 (Zoladex) 3.6 mg
- Where
- 55 sites in India, Japan and 4 more
- Volunteers
- 222 people
- Sponsor
- AstraZeneca
Estrogen Receptor Positive, Male Breast Carcinoma
Lapatinib and Tamoxifen in Treating Patients With Locally Advanced or Metastatic Breast Cancer That Did Not Respond to Previous Tamoxifen
This phase II trial studies how well giving lapatinib ditosylate together with tamoxifen citrate works in treating patients with breast cancer that has spread from where it started to nearby tissue or lymph nodes or to other…
- Conditions
- Estrogen Receptor Positive, Male Breast Carcinoma, Progesterone Receptor Positive, Recurrent Breast Carcinoma
- Trial name
- NCT00118157
- Testing
- Laboratory Biomarker Analysis, Lapatinib Ditosylate, Tamoxifen Citrate
- Where
- 2 sites in United States
- Volunteers
- 19 people
- Sponsor
- National Cancer Institute (NCI)
Breast Cancer
CDK 4/6 Inhibitor, Ribociclib, With Adjuvant Endocrine Therapy for ER-positive Breast Cancer
This research study is studying a drug as a possible treatment for ER-positive Breast Cancer The drug involved in this study is: -Ribociclib
- Trial name
- LEADER (NCT03285412)
- Testing
- Ribociclib, Endocrine therapy
- Where
- 3 sites in United States
- Volunteers
- 120 people
- Sponsor
- Massachusetts General Hospital
Metastatic Breastcancer, Estrogen Receptor Positive Breast Cancer
A Phase II Study Evaluating the Role of Androgen Receptors as Targets for Therapy of Pre-treated Post-menopausal Patients With ER/PgR-negative/AR-positive or ER and/or PgRpositive/ AR-positive Metastatic Breast Cancer (ARTT)
A phase II non randomized study evaluating the role of Androgen Receptors as Targets for therapy of pre-treated postmenopausal patients with ER/PgR-negative/AR-positive or ER and/or PgR-positive/AR-positive metastatic breast…
- Conditions
- Metastatic Breastcancer, Estrogen Receptor Positive Breast Cancer, Estrogen Receptor Negative Neoplasm, Progesterone Receptor Positive Tumor
- Trial name
- ARTT (NCT02000375)
- Testing
- DHEA
- Where
- 8 sites in Italy
- Volunteers
- 20 people
- Sponsor
- Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
Breast Cancer
A Trial of Neoadjuvant Everolimus Plus Letrozole Versus FEC in Women With ER-positive, HER2-negative Breast Cancer
This open, randomized pilot feasibility trial is to evaluate the feasibility and effect of neoadjuvant everolimus plus letrozole versus neoadjuvant fluorouracil, epirubicin plus cyclophosphamide (FEC) in treating postmenopausal…
- Trial name
- NCT02742051
- Testing
- Everolimus, Letrozole, Fluorouracil
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Breast Cancer, ER Positive Breast Cancer
Role of the Immune Environment in Response to Therapy in Breast Cancer
This is an observational case-control study of tissues collected from women with ER+HER2- breast cancers. The immune environments of these cancers will be compared to triple negative and HER2+ breast cancers.
- Conditions
- Breast Cancer, ER Positive Breast Cancer, HER2-negative Breast Cancer, TNBC - Triple-Negative Breast Cancer
- Trial name
- NCT05396612
- Testing
- Collection of personal health information from women treated at the University of Pennsylvania under an approved HIPAA waiver.
- Where
- United States
- Volunteers
- 300 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Breast Cancer
Probability of OncotypeDx to Reallocate As Low or High Risk of Recurrence Breast Cancer Patients with Uncertain Biology
In some cases of hormone receptor positive, human epidermal growth factor receptor 2 (HER2) negative early breast cancer the benefit of adding adjuvant chemotherapy to hormonal treatment, estimated on the basis of the classical…
- Trial name
- NCT06363812
- Where
- Italy
- Volunteers
- 258 people
- Sponsor
- Fondazione Sandro Pitigliani
Breast Cancer
Biomarkers in Predicting Response to Tamoxifen and Letrozole in Postmenopausal Women With Primary Breast Cancer Treated on Clinical Trial CAN-NCIC-MA17
RATIONALE: Studying samples of tumor tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
- Trial name
- NCT00897065
- Testing
- microarray analysis, polymerase chain reaction, protein expression analysis
- Where
- United States
- Volunteers
- 957 people
- Sponsor
- Massachusetts General Hospital
Breast Cancer
Anti-Tumor Immunity Induced by Cryoablation of Invasive Breast Cancers
This protocol will study the impact of cryoablation on immune response in patients diagnosed with invasive breast cancers smaller than 1.5 cm. It will profile the immune response to cryoablation of invasive breast cancers.
- Trial name
- NCT01856036
- Testing
- Cryoablation
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Saint John's Cancer Institute
Postmenopausal Women, Locally Advanced Metastatic Breast Cancer
Safety and Efficacy of RAD001 (Everolimus) in Combination With Letrozole in the Treatment of Postmenopausal Women With Locally Advanced or Metastatic Breast Cancer
This was a multi-center, Israeli phase II open label study evaluating treatment with RAD001 (10 mg daily) combined with letrozole (2.5 mg daily) in postmenopausal women after recurrence or progression on Tamoxifen, Anastrozole or…
- Conditions
- Postmenopausal Women, Locally Advanced Metastatic Breast Cancer, Metastatic Breast Cancer
- Trial name
- NCT01231659
- Testing
- Everolimus, Letrozole
- Where
- 7 sites in Israel
- Volunteers
- 72 people
- Sponsor
- Novartis Pharmaceuticals
Advanced Solid Malignancy, Safety and Tolerability
Safety, Tolerability & Potential Anti-cancer Activity of Increasing Doses of AZD5363 in Different Treatment Schedules
This study is designed to investigate the safety and tolerability of a new drug, AZD5363, in patients with advanced cancer - and to identify a dose and schedule that can be used in the future.
- Conditions
- Advanced Solid Malignancy, Safety and Tolerability, Pharmacokinetics, Pharmacodynamics
- Trial name
- NCT01226316
- Testing
- AZD5363
- Where
- 34 sites in United States, Canada and 8 more
- Volunteers
- 285 people
- Sponsor
- AstraZeneca
HER2-negative Breast Cancer
A Study to Investigate the Biological Effects of AZD9833 in Women With ER-positive, HER2 Negative Primary Breast Cancer
This is a randomised, open-label, parallel-group, pre-surgical study aimed to investigate the biological effects, safety, tolerability, and pharmacokinetics (PK) of different doses of oral AZD9833 in post-menopausal women with…
- Trial name
- SERENA-3 (NCT04588298)
- Testing
- AZD9833
- Where
- 12 sites in Georgia, Mexico and 1 more
- Volunteers
- 135 people
- Sponsor
- AstraZeneca
Malignant Neoplasm of Female Breast
Phase II Trial for Large ER-Negative Breast Cancers
A primary objective of this study is to evaluate the in vivo response of tumor to chemotherapy through gene microarray analysis.
- Trial name
- NCT01869192
- Testing
- Epirubicin, Cyclophosphamide, Docetaxel
- Where
- United States
- Volunteers
- 72 people
- Sponsor
- University of Colorado, Denver
Metastatic Breast Cancer, Advanced Breast Cancer
Patterns of Prescribing and Monitoring of Palbociclib
The purpose of this study is to determine if patients with ER+, human epidermal growth factor 2 negative (HER2-), advanced breast cancer are receiving dosing adjustments and monitoring based on manufacturer recommendations at a…
- Conditions
- Metastatic Breast Cancer, Advanced Breast Cancer, Estrogen Receptor-positive Breast Cancer, Human Epidermal Growth Factor 2 Negative Carcinoma of Breast
- Trial name
- NCT03285568
- Testing
- Palbociclib
- Volunteers
- 67 people
- Sponsor
- Rush University Medical Center